David Langley

Title: David Langley - Innovator in Thrombin Receptor Antagonism

Introduction

David Langley is a notable inventor based in Hertfordshire, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target thrombin receptors. His work has implications for the treatment of various cardiovascular conditions.

Latest Patents

David Langley holds a patent for a compound possessing potent thrombin receptor antagonist activity. The subject invention concerns eryloside F, a novel disaccharide of the steroidal carboxylic acid penasterol. This compound can be isolated from an extract of the marine sponge. Eryloside F is recognized for its ability to act as a potent thrombin receptor antagonist and inhibit human platelet aggregation. Additionally, longer chain penasterol oligosaccharides were isolated and characterized, although these exhibited weaker activity than eryloside F. The invention also includes methods for inhibiting thrombin receptor activity and platelet aggregation through the administration of eryloside F, or its salts, derivatives, or analogs.

Career Highlights

Throughout his career, David Langley has focused on innovative approaches to drug development. His research has led to advancements in understanding how specific compounds can modulate biological pathways related to thrombin receptors. This work is crucial for developing new therapeutic strategies.

Collaborations

David has collaborated with notable colleagues, including Paul Stead and Amy E Wright. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

David Langley's contributions to the field of thrombin receptor antagonism highlight his innovative spirit and dedication to advancing medical science. His patent on eryloside F represents a significant step forward in the search for effective treatments for cardiovascular diseases.